The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a ...
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: COMPASS (WJOG5610L) In the PETHEMA/GEM2012MENOS65 ...
Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study Multiparameter flow cytometry (MFC) was used to assess MRD after induction ...
New tools for monitoring multiple myeloma were a key topic at the European Hematology Society Congress. Advances in drugs and combinations have revolutionized the landscape in multiple myeloma, thus ...
In a large analysis presented at ASH's annual meeting, researchers reported that patients' MRD status after intensive chemo can predict their survival.
Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...
In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today: ...
Researchers at the Cima University of Navarra (Spain), in collaboration with the Spanish Myeloma Group (GEM-PETHEMA), have developed a calculator that identifies patients with multiple myeloma and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback